Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 12, 2024
Data Byte
Candel leads biotech gainers amid wave of data readouts
Prostate cancer data lead to a nearly 70% stock bump; dermatitis data sink Q32 shares
BioCentury | Oct 19, 2024
Finance
Cash raises for Inventiva, Akeso, Capricor
Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on
BioCentury | Sep 5, 2024
Data Byte
FDA’s new drug approvals in August include a Dupixent competitor, a targeted glioma therapy, and more
Agency approved seven new therapies in August, plus four new product formulations or dosages
BioCentury | Aug 3, 2024
Data Byte
Seven more PDUFA dates in August
After starting the month with two approvals, FDA’s remaining decisions include Gilead’s seladelpar, Regeneron’s BCMAxCD3 bispecific
BioCentury | Jul 29, 2024
Deals
Deals Report: GSK is latest pharma to draw on Flagship portfolio
Plus: Day One’s ex-U.S. deal with Ipsen; Novartis taps Dren Bio’s oncology platform; BI buys Avalon-backed Nerio; and Collegium’s ADHD takeout
BioCentury | Jul 27, 2024
Data Byte
Junshi’s PD-1 among seven new products recommended by EMA’s CHMP
Plus: Astellas’ Vyloy on track to become EU’s first CLDN18.2 therapy, and 11 products likely headed for label expansions
BioCentury | Jul 17, 2024
Data Byte
FDA’s five NME approvals in June bring 1H24 total to 21
Ipsen’s Iqirvo, Geron’s Rytelo among June highlights
BioCentury | Mar 19, 2024
Product Development
Clinical report: Crinetics ready to advance oral acromegaly therapy to FDA
Plus: Phase IIb setback for Spruce, Inventiva combination in MASH, and more
BioCentury | Mar 14, 2024
Finance
Venture Report: Tubulis’ big B round to advance ADCs, Relation adds to seed financing
Plus new rounds for Mission, Asgard and more
BioCentury | Feb 12, 2024
Deals
Completing long comeback, liver play CymaBay agrees to $4.3B Gilead takeout
Gilead adds seladelpar, a PBC candidate now under priority review, to liver disease arsenal
Items per page:
1 - 10 of 508